Generate Biomedicines (GENB) Reports $87.7M Q3 Net Loss; Cash Runway Into H1 2028

Generate Biomedicines reported Q3 2026 net loss of $87.7M versus $60.0M in Q3 2025. Cash, equivalents and marketable securities were $404.2M at Sept. 30, compared with $457.4M at June 30; the company expects funding into H1 2028, including its $30.0M Zealand upfront payment received in October.Mate…